Curis Q3 2025 Earnings Report

Curis EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.62
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Curis Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $2.86 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Curis Announcement Details

• Quarter: Q3 2025
• Date: 11/13/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, November 13, 2025
• Conference Call Time: 8:30AM ET

Curis (NASDAQ:CRIS) is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors. The company’s earlier success includes the development of vismodegib, marketed as Erivedge® through a collaboration and subsequent acquisition by Genentech, for the treatment of advanced basal cell carcinoma. Curis continues to pursue partnerships to advance its pipeline and leverage external expertise for product registration and commercialization.

Founded in 1997 and headquartered in Lexington, Massachusetts, Curis operates research facilities in the greater Boston area and collaborates with academic institutions and industry partners worldwide. The company’s integrated discovery and development platform has been instrumental in generating therapeutic candidates across multiple cancer indications, with a strategic focus on precision medicines that offer the potential for improved patient outcomes and differentiated safety profiles.

Curis is led by President and Chief Executive Officer Ali Fattaey, Ph.D., who joined the company in 2019 and brings extensive experience in oncology research and drug development. The senior management team comprises seasoned professionals in clinical development, regulatory affairs and commercial strategy, underscoring Curis’ commitment to advancing its pipeline candidates through critical regulatory milestones and toward potential market approval.